Surface modification of PLGA nanoparticles with biotinylated chitosan for the sustained in vitro release and the enhanced cytotoxicity of epirubicin

Functionalizing PLGA and PLGA Derivatives for Drug Delivery and Tissue Regeneration Applications

“…[155] Hongli et al studied the success of biotinylated chitosan PLGA nanoparticles as a new functionalized PLGAbased DDS for cancer therapy, and it was shown an enhancement of the therapeutic effect of epirubicin and nanoparticles internalization. [156] Covalent conjugations in turn, are more stable, originating novel materials with different safety/toxicity profiles. Herein, the most used reaction is the carbodiimide one, which originates an amide group by the conjugation of the carboxylic end groups of PLGA and the amine end groups of the ligands.…”

Toxicity, pharmacokinetics, and in vivo efficacy of biotinylated chitosan surface-modified PLGA nanoparticles for tumor therapy

“…Bio-CS was synthesized according to our previous published work (Chen et al 2016). In brief, biotin (0.5 mol), dicyclohexylcarbodiimide (DCC, 0.5 mol), and N-hydroxysuccinimide (NHS, 0.6 mol) were mixed in 20 mL DMF followed by stirring for 18 h. The reaction mixture was filtered and the excess of diethyl ether was then added to get the precipitate of NHSbiotin.…”

“…Briefly, 20 mg of EPB-loaded NPs was suspended in 5 mL of PBS and vibrated in a water-bath shaker at 75 rpm at 37 C. At designated time intervals, all samples were centrifuged at 15,000 rpm for 10 min, the supernatants were taken out for the detection of EPB content and 5 mL of fresh release media were then added at the same time. The EPB release amounts were determined by HPLC analysis as described (Chen et al , 2016. For the evaluation of the release kinetics, the release data were fitted into first-order, zero-order, and Higuchi models.…”

“…In our previous reports, we prepared biotinylated chitosan (Bio-CS)-based surface modified PLGA NPs to be used as drug carriers (Chen et al 2009, and also found that using Bio-CS conjugate as a surface-modified material could realize the distribution of functional biotin groups on the surface of PLGA NPs. In MCF-7 tumor-bearing nude mice, Bio-CS-PLGA NPs were mainly distributed in the tumor after 24 h post administration (Chen et al 2016). But the biological effects of Bio-CS-PLGA NPs in vivo have not been investigated deeply up to date.…”

Synthesis and characterization of targeted bar encapsulated polylactic-co-glycolic acid nanoparticles to inhibit porphyromonas gingivalis biofilm formation.

“…One method of achieving targeting is to surface modify NPs with proteins or drugs to achieve specific targeting or binding properties. In addition to specifically targeting delivery to particular niches (here in the oral cavity), surface modification may decrease the initial release of encapsulant from the NPs, aiding in prolonged release (49)(50)(51). Basic rationale here is to use a bacterial surface protein that can aid in targeting these NPs to the areas in oral cavity where P. gingivalis is present.…”